I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APAO 2024

-
Coming soon
03:00 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Faricimab▼ Treatment Outcomes With Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
Chang A, Lim J, Singer M, Idowu O, Hill L, Gibson K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:04 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Biomarkers for Vascular Stability Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition With Faricimab▼ in Phase 3 Trials in DME
Szeto S, Tan C, Maunz A, Patel K, von Schulthess E, Wang T, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:08 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, Durability and Safety of Faricimab▼ in nAMD: 48-Week Results From the China Subpopulation of Phase 3 LUCERNE
Chen Y, Zhang M, Sun D, Li S, Patel S, Liu R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:12 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Li X, Sun X, Jiang Q, Idowu O, Tang Y, Liu R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:26 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials
Tan A, Singer M, Hill L, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:08 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Results From the Portal 5-Year Subgroup Analysis
Hwang DK, Cheung G, Howard J, Nielsen J, Singh N, Cavichini Cordeiro M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:32 PM
Duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): Results From the Phase 3 Pagoda and Pavilion Trials
Sagong M, Emanuelli A, Holekamp N, Heinrich D, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:40 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Eyes With Neovascular Age-Related Macular Degeneration
Chaikitmongkol V, Khanani A, Margaron P, Souverain A, Patel S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:44 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Macular Leakage in DME With Faricimab▼ vs Aflibercept
Tan G, Goldberg R, Nudleman E, Sivaprasad S, Wang T, Mar F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar